MARKET WIREStocktwits • 1d ago
PBYI: Puma Biotechnology Inc Latest Stock Price, Analysis, News and Trading IdeasStocktwits report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
Why PBYI Stock dropped -2.49% Today — RQD Quant Desk Flash
$10.18 -2.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.16
Puma Biotechnology Inc (PBYI) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (74.5% gross margin, 29% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B- • BUY
Cap $538.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PBYI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PBYI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Puma Biotechnology Inc (NASDAQ: PBYI) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $10.18 (-2.49% 1D, market cap $538.9M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 17/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, PBYI ranks #78 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PBYI compare to DRUG and EVO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBYI carries a Roarable B- (70/100 RQD), trailing P/E of 17.5x, gross margin of 74.5%, and ROIC of 29.3%. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $539.9M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PBYI?
▼
Per PBYI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401667), Puma Biotechnology Inc generated $228.4M in revenue (-0.9% YoY), $31.1M in net income, and $41.7M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.16 (-0.21%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 18.3% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B-
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw B · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBYI)Realized 20D OHLCV Swing Band: ±8.9%
Deterministic 5-Pillar Attribution (70/100 Composite)
🔍 WHY PBYI SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+17/20 pts (24% of score)
FRED Regime × Technicals: 81% of 52W Range • RSI-14 at 52.6 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk9/20 pts (-11 pt drag)
Balance-sheet & 10-K footnote risk deducts 11 pts from forensic ceiling
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$10.12+6.3% Next Q
62
Q2 (-2Q)Grade C+$10.76+1.5% Next Q
65
Q3 (-1Q)Grade B-$10.92-6.8% Next Q
67
CurrentGrade B-$10.18+6.6% Hist 90D α
70
Trajectory: C+ (62) → B- (70)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the PBYI Bull Thesis Could Fail
Even with a 70/100 (B-) score, PBYI faces multiple-compression risk if 17.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 72.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.87) or 200D SMA ($7.95) invalidates the momentum regime and cuts Target Base ($10.73) toward Bear Floor ($8.35).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBYI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PBYI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PBYI Stock dropped -2.49% Today — RQD Quant Desk Flash
Puma Biotechnology Inc (PBYI) dropped -2.49% to $10.18, trading at 81% of its 52-week range ($4.58 – $11.5). High-quality cash engine (74.5% gross margin, 29% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 81% of its 52-week range ($4.58 – $11.5) with RSI-14 at 52.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.9% around $10.18 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 74.5% gross margin and $41.7M annual free cash flow.
Live PBYI Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com • 1d ago
how InvestingPro’s fair value caught Puma Biotech’s 95% surge By Investing.comInvesting.com report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?TradingView report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial ResultsYahoo Finance report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Puma Biotechnology stock gets higher 2026 Nerlynx outlookad-hoc-news.de report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 2d ago
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema OncologyYahoo Finance report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 18d ago
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthAZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (PBYI Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PBYI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +35.19%▼ SUPPORT BREAKDOWN
2026-11-03O $10.54H $10.54L $10.18C $10.18VOL 339.6K
RES: $11.80SUP: $10.24SMA50: $9.87SMA200: $7.95
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PBYI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
10.5%/yr Implied 5Y Growth
vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on PBYI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PBYI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PBYI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBYI)
Health Care Rank #78 of 1015
⚔️ DRUG vs PBYI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PBYI vs. DRUG, EVO, NGNE, STTK)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Puma Biotechnology Inc (PBYI) ranks #78 by composite RQD confidence (70/100, grade B-) and #429 by equity capitalization ($538.9M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently leads its immediate peer cohort in composite quantitative strength at 70/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PBYI
ACTIVE
Puma Biotechnology Inc | B- | 70/100 | 17.5x | 74.5% | 29.3% | -2.49% | $538.9M | Benchmark Subject |
| DRUG Bright Minds Biosciences Inc. | D | 46/100 | — | — | — | -52.35% | $539.9M | /drug-vs-pbyi → |
| EVO Evotec SE | D | 47/100 | — | — | — | -0.65% | $544.3M | /evo-vs-pbyi → |
| NGNE Neurogene Inc. | D- | 36/100 | — | — | -35.0% | -3.41% | $551.3M | /ngne-vs-pbyi → |
| STTK Shattuck Labs Inc. | E | 29/100 | — | — | -35.0% | -4.32% | $558.0M | /sttk-vs-pbyi → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001401667 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Puma Biotechnology Inc (PBYI) reported GAAP revenue of $228.4M (-0.9% vs. FY2024 revenue of $230.5M , and -3.1% cumulative change since FY2023) , GAAP net income of $31.1M, operating cash flow of $41.8M, and free cash flow of $41.7M (+7.4% YoY). On the balance sheet, PBYI closed FY2025 with $216.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $228.4M | $31.1M | $41.8M | $41.7M | $216.3M | $0 |
| FY2024 (FY) | 2024-12-31 | $230.5M | $30.3M | $38.9M | $38.9M | $213.3M | $21.7M |
| FY2023 (FY) | 2023-12-31 | $235.6M | $21.6M | $27.0M | $27.0M | — | — |
3. PBYI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PBYI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Puma Biotechnology Inc (NASDAQ: PBYI) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $10.18 (-2.49% 1D, market cap $538.9M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 17/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, PBYI ranks #78 in composite RQD confidence.
How does PBYI compare to DRUG and EVO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBYI carries a Roarable B- (70/100 RQD), trailing P/E of 17.5x, gross margin of 74.5%, and ROIC of 29.3%. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $539.9M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PBYI?
Per PBYI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401667), Puma Biotechnology Inc generated $228.4M in revenue (-0.9% YoY), $31.1M in net income, and $41.7M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PBYI trading relative to its 50-day, 200-day, and 52-week technical levels?
PBYI last traded at $10.18 (-2.49% on volume of 399,317 shares), positioning the stock +3.14% above its 50-day simple moving average ($9.87) and +28.05% above its 200-day simple moving average ($7.95). Across its 52-week range of $4.58 to $11.50, PBYI sits at the 80.9% percentile with a 14-day RSI of 52.6 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($9.27 to $11.09).
ROARABLE RATING BRIEF • RQD 70/100 (B-)
✓ SEC XBRL & RQD VERIFIED
PBYI — Puma Biotechnology Inc: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Puma Biotechnology Inc (PBYI) earns a live Roarable RQD composite score of 70/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $10.18 (-2.49% 1D, market capitalization $538.9M).
- Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 29.3%, gross margin of 74.5%, operating margin of 16.3%, and free cash flow yield of 7.67%.
- Whale 13F & Options Flow (13/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (17/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 8/9, and Debt/Equity of 0.00x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Puma Biotechnology Inc is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.5B. — for further detail on what the company sells or to whom.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Puma Biotechnology Inc (PBYI) reported $228.4M in annual revenue (up from $230.5M in FY2024, -0.9% YoY) and $31.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($235.6M revenue, $21.6M net income) through FY2025, PBYI scaled operating cash flow to $41.8M and free cash flow to $41.7M, backed by $216.3M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (B- • RQD 70/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 7.67% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $4.58 – $11.50 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh 17.5x trailing P/E and 13.8x EV/EBITDA against 16.3% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
— The Butterfly Supply-Chain Graph records supply_chain as NONE, with empty butterfly_links and proprietary_signals arrays, so upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided sources.
- Key Question #1: Can PBYI sustain or expand its 16.3% operating margin and 29.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $228.4M and free cash flow of $41.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is PBYI's 16.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
PBYI Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Puma Biotechnology Inc (PBYI) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stocktwits • 1d ago
PBYI: Puma Biotechnology Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com • 1d ago
how InvestingPro’s fair value caught Puma Biotech’s 95% surge By Investing.com Investing.com report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3? TradingView report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript Benzinga report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results Yahoo Finance report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Puma Biotechnology stock gets higher 2026 Nerlynx outlook ad-hoc-news.de report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 2d ago
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology Yahoo Finance report covering Puma Biotechnology Inc (PBYI) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PBYI Bull vs. Bear Conversation Board — What's Your Call at $10.18?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PBYI 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $13.47 (+29.0%)
📌 Pinned Debate The RQD rating's insider-conviction (17/20) and macro-fit (17/20) pillars, combined with a 29.3% ROIC and 7.67% FCF yield, point to a c
The street is overcomplicating Puma Biotechnology Inc (PBYI). The RQD rating's insider-conviction (17/20) and macro-fit (17/20) pillars, combined with a 29.3% ROIC and 7.67% FCF yield, point to a cash-generative business with institutional accumulation behind it.. With an RQD score of 70/100 (B-) and Forensic Balance Sheet at 9/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $11.28.
EarningsSniper 🐂 BULL
@CreditSpread_Watch Shorting a 13/20 institutional whale-flow stock at $10.44 is dangerous when funds are rotating into Health Care.
CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH
🎯 Target: $7.93 (-24.0%)
Spot @ $10.44 A 0.2 Altman Z-Score and a 9/20 forensic balance-sheet pillar flag financial-distress risk, and the stock trades near the top of its $4
Sitting on the sidelines or leaning short PBYI above $10.44. A 0.2 Altman Z-Score and a 9/20 forensic balance-sheet pillar flag financial-distress risk, and the stock trades near the top of its $4.58–$11.5 52-week range with reported revenue declining since FY 2023.. Until Fundamental Cash Engine (14/20) and FCF yield (7.67%) inflect higher, upside is capped near $11.50.